Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125456462 | 12545646 | 2 | F | 2014 | 20160707 | 20160711 | 20160719 | EXP | DE-TEVA-674885GER | TEVA | GOERIG N, SEMRAU S, FREY B, KORN K, FLECKENSTEIN B, ?BERLA K ET AL. CLINICALLY SIGNIFICANT CMV (RE)ACTIVATION DURING OR AFTER RADIOTHERAPY/CHEMOTHERAPY OF THE BRAIN: CORRELATION WITH NEUROLOGICAL DETERIORATION AND IMPROVEMENT UPON ANTIVIRAL TREATMENT.STRAHLENTHERAPIE UND ONKOLOGIE. 2016; 1-9 | 59.00 | YR | M | Y | 0.00000 | 20160719 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125456462 | 12545646 | 1 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | 12 MILLIGRAM DAILY; FOUR MILLIGRAM THREE TIMES DAILY FROM ONSET | U | 0 | 4 | MG | TID | |||||||
| 125456462 | 12545646 | 2 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | U | 0 | |||||||||||
| 125456462 | 12545646 | 3 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | U | 0 | |||||||||||
| 125456462 | 12545646 | 4 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | U | 0 | |||||||||||
| 125456462 | 12545646 | 5 | PS | CISPLATIN. | CISPLATIN | 1 | KOF; 100%; Q29; Q57 | U | 74656 | 90 | MG/M**2 | ||||||||
| 125456462 | 12545646 | 6 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | KOF; 100%; Q29; Q57 | U | 74284 | 270 | MG/M**2 | ||||||||
| 125456462 | 12545646 | 7 | SS | MANNITOL. | MANNITOL | 1 | 20 % ONCE DAILY FOR THREE DAYS FROM ONSET | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125456462 | 12545646 | 1 | Agitation |
| 125456462 | 12545646 | 2 | Ataxia |
| 125456462 | 12545646 | 3 | Disorientation |
| 125456462 | 12545646 | 4 | Incontinence |
| 125456462 | 12545646 | 5 | Nasal sinus cancer |
| 125456462 | 12545646 | 6 | Nasal sinus cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125456462 | 12545646 | OT |
| 125456462 | 12545646 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125456462 | 12545646 | Agitation | |
| 125456462 | 12545646 | Ataxia | |
| 125456462 | 12545646 | Cytomegalovirus infection | |
| 125456462 | 12545646 | Disorientation | |
| 125456462 | 12545646 | Drug ineffective | |
| 125456462 | 12545646 | Incontinence | |
| 125456462 | 12545646 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |